[go: up one dir, main page]

WO2004064813A1 - Improvements in or relating to anti-aromatase composition - Google Patents

Improvements in or relating to anti-aromatase composition Download PDF

Info

Publication number
WO2004064813A1
WO2004064813A1 PCT/US2003/001205 US0301205W WO2004064813A1 WO 2004064813 A1 WO2004064813 A1 WO 2004064813A1 US 0301205 W US0301205 W US 0301205W WO 2004064813 A1 WO2004064813 A1 WO 2004064813A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
range
contain
aromatase
seed oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/001205
Other languages
French (fr)
Inventor
Michael Donald Farley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2003203010A priority Critical patent/AU2003203010A1/en
Priority to PCT/US2003/001205 priority patent/WO2004064813A1/en
Publication of WO2004064813A1 publication Critical patent/WO2004064813A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond

Definitions

  • This testosterone/ estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.
  • testosterone/estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone.
  • DHEA projesterone androstenedione
  • estrone aldosterone cortisol
  • estradiol estradiol
  • dihydrotestoasterone dihydrotestoasterone.
  • These hormones which directly effect testosterone and estrogen ratios also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy. It is well established, that as a human being ages, these testosterone/ estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.
  • the present invention includes an anti-aromatase pharmaceutical or more specifically a nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; b. Pumpkin seed oil (c-u ⁇ _ubita pepo) m the range of about 150 mg. to about 205 mg.;
  • Tables I and II depict Aromatisation structure that are beneficial to the method of treatment of various ailments, for example, benign prostate hyperthrophy, some forms of breast cancer, and in the treatment of osteoporsis, etc.
  • the present invention relates to a totally new application of several naturally occurring aromatase inhibitors which interupt several stages in the presented hormone panel (Table I), which illustrates the currently accepted normal aromatization sequence.
  • This invention also incorporates for the first time, an inhibitor of sex hormone binding globulin which allows bioavailable hormone to remain active at target tissue sites for a longer period of time.
  • the present invention includes an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c.
  • Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 g.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • this invention is an anti-aromatase capsule or dose in commpound form in which the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and
  • this invention resides in an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 g.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the present invention is an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical or nutraceutical composition of which each capsule Or dose consists of: a.
  • Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
  • the invention resides in a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase pharmaceutical or nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Urtica dioica) 16:1 in the range of about 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention provides a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.
  • Pumpkin seed oil Cucubita pepo
  • Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterol
  • the invention assists a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituting an anti- aromatase capsule or dose compound form in which the composition for the maintenance of testosterone/ estrone ratios with the anti-aromatase composition being characterized by: a. Nettle root extract (Uritical dioica) 16:1 of 275 mg. to above 350 mg.; • b. ' Pumpkin seed oil (Cucubita pepo) of 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols of 20 mg. to about 40 mg.; and d. Chrysin of 475 mg. to 550 mg.
  • a. Nettle root extract (Uritical dioica) 16:1 of 275 mg. to above 350 mg.
  • b. ' Pumpkin seed oil Cucubita pepo) of 150 mg. to about 205 mg.
  • a method of treatment utilizing a specific nutraceutical or pharmaceutical anti-aromatase composition so as to maintain the testerone/esttone ratios said composition is characterized by: a. Chrysin of 500 mg.; b. Nettle root extract (Uritica dioica) of 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and 25 mg.
  • the invention also includes a method of treatment utilizing a pharmaceutical or nuttaceutical composition cosisting of a dosage or capsule constituting an anti-aromatase capsule or dose in compound form in which the composition consists of: a. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13 ⁇ total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
  • the invention furthermore includes a method of treatment utilizing a nutraceutical or a pharmaceutical composition consisting of a dosage or capsule constituted by an anti- aromatase capsule or dose in compound form comprising a formula in the composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus af ricana) bark extract stadardized to contain 13% total sterols and about 25 mg.
  • Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg.
  • Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg.
  • ⁇ Pygeum Africanum (Prunus africana) bark exttact standardized to contain at least 12 to 14% of total sterols in the range of about 20 to 40 mg. and Chrysin in the range of 475 to 550 mg. This composition assists in the tteatment of benign prostate hyperthropy and breast cancer etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An anti-aromatase nutraceutical or pharmaceutical composition, consisting of a capsule or dose to contain:Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg; Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg; Pygeum Africanum (Prunus africana) bark extract standardized to contain at least 12 to 15% of total sterols in the range of about 20 to 40 mg, and Chrysin in the range of 475 to 550 mg. This composition assists in the treatment of benign prostate hyperthropy and breast cancer, etc. and also a method of utilizing the composition.

Description

Improvements In Or Relating To Anti-Aromatase Composition
It is known, that throughout life of a mammal or a human being, testosterone/ estrone ratios do have a considerable effect on mammal or human life.
This testosterone/ estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.
It is advantageous that testosterone/estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone. These hormones which directly effect testosterone and estrogen ratios, also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy. It is well established, that as a human being ages, these testosterone/ estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.
It is known from the specification of U.S. Patent No.4,598,072 to Schweibert et.al dated July 1, 1986 to provide for an aromatase inhibitor and an antiandrogen which generally is applicable for the treatment of prostatic hyperglania, incorporated herein by reference only.
Furthermore, it is known from the specification of U.S. Patent No. 5,972,921 to Santti etal dated October 26, 1999 in the use of an aromatase inhibitor administered for the specific treatment for men for detrusor wrethral dyssynergia. This is incorporated herein for reference only.
It is also known from the specification of U.S. Patent No.5,861,389 to Radlmaier etal dated January 19, 1999 for specific treatment of only androgen deficiency in men using selective aromatase inhibitors. This is incorporated herein for reference only.
The present invention includes an anti-aromatase pharmaceutical or more specifically a nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; a. Nettle root extract (Uritica dioica) 16:1 in the range of about 275 mg. to about 350 mg; b. Pumpkin seed oil (c-u<_ubita pepo) m the range of about 150 mg. to about 205 mg.;
5 c. Pygeum Africanum (prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg. However, the present invention also relates to a totally new use of a male hormone 10 panel aromatasition structure with an androgen pathway as depicted at Table I and -T, also for breast cancer and other related treatments.
TABLE I
Figure imgf000003_0001
TABLE π Normai βange of Hormone Values
Figure imgf000003_0002
Both Tables I and II depict Aromatisation structure that are beneficial to the method of treatment of various ailments, for example, benign prostate hyperthrophy, some forms of breast cancer, and in the treatment of osteoporsis, etc.
Specifically, the present invention relates to a totally new application of several naturally occurring aromatase inhibitors which interupt several stages in the presented hormone panel (Table I), which illustrates the currently accepted normal aromatization sequence. This invention also incorporates for the first time, an inhibitor of sex hormone binding globulin which allows bioavailable hormone to remain active at target tissue sites for a longer period of time. Suitably, the present invention includes an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 g.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
Conveniently, this invention is an anti-aromatase capsule or dose in commpound form in which the pharmaceutical or nutraceutical composition consists of: a. Pumpkin seed oil (Cucubita pepo) of about 175 mg; b. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg; and d. Chrysin in the range of about 475 mg. to about 550 mg. Advantageously, this invention resides in an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Phgeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 g.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg. Moreover, the present invention is an anti-aromatase capsule or dose in compound form comprising a formula in the pharmaceutical or nutraceutical composition of which each capsule Or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and about 25 mg.
In addition, the invention resides in a method of treatment utilizing a pharmaceutical composition consisting of a dosage or capsule constituted by an anti-aromatase pharmaceutical or nutraceutical composition in dose compound form comprising a formula in which each capsule or dose consists of: a. Nettle root extract (Urtica dioica) 16:1 in the range of about 275 mg. to above 350 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
Also, the invention provides a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituted an anti-aromatase capsule or dose in compound form in which the pharmaceutical or nutraceutical composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of about 300 mg.; b. Pumpkin seed oil (Cucubita pepo) in the range of about 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols in the range of about 20 mg. to about 40 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg. Furthermore, the invention assists a method of treatment utilizing a pharmaceutical or nutraceutical composition consisting of a dosage or capsule constituting an anti- aromatase capsule or dose compound form in which the composition for the maintenance of testosterone/ estrone ratios with the anti-aromatase composition being characterized by: a. Nettle root extract (Uritical dioica) 16:1 of 275 mg. to above 350 mg.; •b. ' Pumpkin seed oil (Cucubita pepo) of 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols of 20 mg. to about 40 mg.; and d. Chrysin of 475 mg. to 550 mg.
Advantageously, a method of treatment utilizing a specific nutraceutical or pharmaceutical anti-aromatase composition so as to maintain the testerone/esttone ratios, said composition is characterized by: a. Chrysin of 500 mg.; b. Nettle root extract (Uritica dioica) of 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and 25 mg. The invention also includes a method of treatment utilizing a pharmaceutical or nuttaceutical composition cosisting of a dosage or capsule constituting an anti-aromatase capsule or dose in compound form in which the composition consists of: a. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13Λ total sterols and about 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; c. Nettle root extract (Urtica dioica) 16:1 of about 300 mg.; and d. Chrysin in the range of about 475 mg. to about 550 mg.
The invention furthermore includes a method of treatment utilizing a nutraceutical or a pharmaceutical composition consisting of a dosage or capsule constituted by an anti- aromatase capsule or dose in compound form comprising a formula in the composition of which each capsule or dose consists of: a. Chyrsin of about 500 mg.; b. Nettle root extract (Urtica dioica) of about 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of about 175 mg.; and d. Pygeum Africanum (Prunus af ricana) bark extract stadardized to contain 13% total sterols and about 25 mg. An anti-aromatase nutraceutical or pharmaceutical composition, consisting of inc apsule or dose to contain:
Nettle root extract (Urtica dioica) 16:1 in the range of about 275 to 350 mg. Pumpkin seed oil (Cucubita pepo) in the range of about 150 to 205 mg.
■Pygeum Africanum (Prunus africana) bark exttact standardized to contain at least 12 to 14% of total sterols in the range of about 20 to 40 mg. and Chrysin in the range of 475 to 550 mg. This composition assists in the tteatment of benign prostate hyperthropy and breast cancer etc.

Claims

Claims
1. A method of tteatment utilizing a pharmaceutical or nutraceutical anti-aromatase composition for the maintenance of testostrone/ estrone ratioos said anti-aromatase composition is characterized by: a. Nettle root extract (Uritica dioica) 16:1 of 275 to above 350 g.; b. Pumpkin seed oil (Cucubita pepo) of 150 mg. to about 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain about 12 to 14% of total sterols of 20 mg. to about 40 g.; and d. Chrysin of 475 mg. to 550 mg.
2. A method of treatment as claimed in claim 1, wherein the composition consists of: a. Nettle root extract (Uritica dioica) 16:1 of 300 mg.; b. Pumpkin seed oil (Cucubita pepo) of 150 mg. to 205 mg.; c. Pygeum Africanum (Prunus africana) bark extract standarized to contain about 12 to 14% of total sterols of 20 mg. to 40 mg.; and d. Chrysin of 475 mg. to 550 mg.
3. A method of treatment as claimed in claim 1, wherein the composition comprising: a. Pumpkin seed oil (Cucubita pepo) of 175 mg.; b. Nettle root extract (Uritica dioica) 16:1 of 300 mg.; c. Pygeum Africanum (Prunus africana) bark extract standardized to contain 12 to 14 % of total sterols of 20 mg. to 40 g.; and d. Chrysin of 475 mg. to 550 mg.
4. A method of treatment utilizing a composition as claimed in claim 1, wherein the composition comprising: a. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and 25 mg.; b. Pumpkin seed oil (Cucubita pepo) of 175 mg.; c. Nettle root extract (Uritica dioica) 16:1 of 300 mg.; and d. Chrysin in the range of about 475 mg. to 550 mg.
5. A method of treatment utilizing a nutraceutical or pharmaceutical anti-aromatase composition for the maintenance of testerone/esttone ratios, said composition comprising: a. Chyrsin of 500 mg.; b. Nettle root extract (Uritica dioica) of 300 mg.; c. Pumpkin seed oil (Cucubita pepo) of 175 mg.; and c. Pumpkin seed oil (Cucubita pepo) of 175 mg.; and d. Pygeum Africanum (Prunus africana) bark extract standardized to contain 13% total sterols and 25 mg.
PCT/US2003/001205 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition Ceased WO2004064813A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003203010A AU2003203010A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition
PCT/US2003/001205 WO2004064813A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/001205 WO2004064813A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Publications (1)

Publication Number Publication Date
WO2004064813A1 true WO2004064813A1 (en) 2004-08-05

Family

ID=32769583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/001205 Ceased WO2004064813A1 (en) 2003-01-13 2003-01-13 Improvements in or relating to anti-aromatase composition

Country Status (2)

Country Link
AU (1) AU2003203010A1 (en)
WO (1) WO2004064813A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284873A (en) * 1991-07-11 1994-02-08 Laboratorios Madaus-Cerafarm, S.A. Pharmaceutical compositions derived from the acid fraction of lipid extracts of sabal serrulata, with adrenergic antagonist activity and method of preparing said composition
US5861389A (en) * 1994-09-22 1999-01-19 Schering Aktiengesellschaft Methods of treating androgen deficiency in men using selective aromatase inhibitors
US6039950A (en) * 1995-04-14 2000-03-21 University Of Southern California Pharmaceutical grade saw palmetto
US20010008638A1 (en) * 1999-07-14 2001-07-19 Brian J. Wilding Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284873A (en) * 1991-07-11 1994-02-08 Laboratorios Madaus-Cerafarm, S.A. Pharmaceutical compositions derived from the acid fraction of lipid extracts of sabal serrulata, with adrenergic antagonist activity and method of preparing said composition
US5861389A (en) * 1994-09-22 1999-01-19 Schering Aktiengesellschaft Methods of treating androgen deficiency in men using selective aromatase inhibitors
US6039950A (en) * 1995-04-14 2000-03-21 University Of Southern California Pharmaceutical grade saw palmetto
US20010008638A1 (en) * 1999-07-14 2001-07-19 Brian J. Wilding Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form

Also Published As

Publication number Publication date
AU2003203010A1 (en) 2004-08-13

Similar Documents

Publication Publication Date Title
Wankhede et al. Beneficial effects of fenugreek glycoside supplementation in male subjects during resistance training: a randomized controlled pilot study
Geller et al. Contemporary alternatives to plant estrogens for menopause
Rowland et al. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions
Steenkamp Phytomedicines for the prostate
Abd Jalil et al. Role of medicinal plants and natural products on osteoporotic fracture healing
Gonzales et al. Effects of different varieties of Maca (Lepidium meyenii) on bone structure in ovariectomized rats
Ogunlakin et al. Ameliorative effect of Kigelia africana (Lam.) Benth. fruit methanol extract in letrozole-induced polycystic ovarian syndrome rat
WO2003000276A1 (en) Anti-aromatase composition consisting of a mixture from plants extracts
EP2705762B1 (en) Biologically active dietary supplement for normalizing the androgen level in men and the overall condition and reducing obesity
WO2004064813A1 (en) Improvements in or relating to anti-aromatase composition
WO2004064814A1 (en) Improvements in or relating to anti-aromatase composition
WO2007141661A2 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia
Zabłocka-Słowińska et al. Interactions between preparations containing female sex hormones and dietary supplements
Mayo A natural approach to menopause
George et al. Acceptance of herbal medicines in andrology
Habib et al. Effect of Moringa Leaves and Seeds on Osteoporosis in Rats
US20080070877A1 (en) Process of epilobium species for treatment of hormone balance in warm blooded animals, and method of manufacturing
EP3750532A1 (en) A food supplement for use in restoring male sex drive (libido)
WO2001087316A2 (en) Composition and method for increasing testosterone levels
Bhattacharya et al. Baldness: Comprehensive aspects and its reassuring remedies
Chinnathambi et al. Exploring phytoandrogens: A review of their potential in health and medicine
Farooq et al. Bioactive compounds from Tribulus Terrestris L.(zygophyllaceae)
Kumari et al. New Emerging Aspect of Herbal Extracts for the Treatment of Osteoporosis: Overview
US20030203043A1 (en) Composition and method for increasing testosterone levels
Geiselman et al. Nutritional Supplementation Approaches to Increase Testosterone Levels in Active Adult Males.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC. ( EPO COMMUNICATION FORM 1205A HAS BEEN SENT ON 26-10-2005)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP